Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.930
+0.060 (2.09%)
At close: Feb 21, 2025, 4:00 PM
3.010
+0.080 (2.72%)
After-hours: Feb 21, 2025, 5:15 PM EST
Vistagen Therapeutics Employees
As of March 31, 2024, Vistagen Therapeutics had 40 total employees, including 39 full-time and 1 part-time employees. The number of employees increased by 6 or 17.65% compared to the previous year.
Employees
40
Change (1Y)
6
Growth (1Y)
17.65%
Revenue / Employee
$17,450
Profits / Employee
-$1,182,600
Market Cap
84.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
VTGN News
- 2 days ago - Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - Business Wire
- 7 days ago - Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication - Seeking Alpha
- 8 days ago - Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - Business Wire
- 16 days ago - Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 - Business Wire
- 17 days ago - Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain - Business Wire
- 5 weeks ago - Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia - Business Wire
- 6 weeks ago - Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder - Business Wire